Minimal residual disease monitoring via AML1-ETO breakpoint tracing in childhood acute myeloid leukemia

[1]  G. Clark,et al.  Measurable Residual Disease in Acute Myeloid Leukemia Using Flow Cytometry: A Review of Where We Are and Where We Are Going , 2020, Journal of clinical medicine.

[2]  I. Glauche,et al.  Analysis of chronic myeloid leukaemia during deep molecular response by genomic PCR: a traffic light stratification model with impact on treatment-free remission , 2020, Leukemia.

[3]  E. Shumilov,et al.  Current concepts and future directions for hemato-oncologic diagnostics. , 2020, Critical reviews in oncology/hematology.

[4]  Y. Okuno,et al.  Detection of subclonal SETBP1 and JAK3 mutations in juvenile myelomonocytic leukemia using droplet digital PCR , 2020, Leukemia.

[5]  Yu-Hong Chen,et al.  Allogeneic hematopoietic stem cell transplantation can improve the prognosis of high-risk pediatric t(8;21) acute myeloid leukemia in first remission based on MRD-guided treatment , 2020, BMC Cancer.

[6]  B. Buldini,et al.  Flow-Cytometric Monitoring of Minimal Residual Disease in Pediatric Patients With Acute Myeloid Leukemia: Recent Advances and Future Strategies , 2019, Front. Pediatr..

[7]  M. Voso,et al.  MRD in AML: The Role of New Techniques , 2019, Front. Oncol..

[8]  R. Foà,et al.  Digital droplet PCR and next-generation sequencing refine minimal residual disease monitoring in acute lymphoblastic leukemia , 2019, Leukemia & lymphoma.

[9]  Daniela Cilloni,et al.  Digital PCR in Myeloid Malignancies: Ready to Replace Quantitative PCR? , 2019, International journal of molecular sciences.

[10]  A. Moore,et al.  Molecular Minimal Residual Disease Monitoring in Acute Myeloid Leukemia: Challenges and Future Directions. , 2018, The Journal of molecular diagnostics : JMD.

[11]  J. Mulloy,et al.  RUNX1-ETO Leukemia. , 2017, Advances in experimental medicine and biology.

[12]  J. Rubnitz.  Current Management of Childhood Acute Myeloid Leukemia , 2017, Pediatric Drugs.

[13]  M. Boccadoro,et al.  Minimal Residual Disease Detection by Droplet Digital PCR in Multiple Myeloma, Mantle Cell Lymphoma, and Follicular Lymphoma: A Comparison with Real-Time PCR. , 2015, The Journal of molecular diagnostics : JMD.

[14]  G. Leverger,et al.  Collaborative Efforts Driving Progress in Pediatric Acute Myeloid Leukemia. , 2015, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[15]  G. Basso,et al.  Minimal residual disease monitored after induction therapy by RQ-PCR can contribute to tailor treatment of patients with t(8;21) RUNX1-RUNX1T1 rearrangement , 2015, Haematologica.

[16]  D. Campana,et al.  Gemtuzumab ozogamicin can reduce minimal residual disease in patients with childhood acute myeloid leukemia , 2013, Cancer.

[17]  Elaine Coustan-Smith,et al.  Comparative analysis of different approaches to measure treatment response in acute myeloid leukemia. , 2012, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[18]  Todd A Alonzo,et al.  Residual disease detected by multidimensional flow cytometry signifies high relapse risk in patients with de novo acute myeloid leukemia: a report from Children's Oncology Group. , 2012, Blood.

[19]  R. Hills,et al.  Minimal residual disease monitoring by quantitative RT-PCR in core binding factor AML allows risk stratification and predicts relapse: results of the United Kingdom MRC AML-15 trial. , 2007, Blood.

[20]  R. Hanada,et al.  Risk-stratified therapy and the intensive use of cytarabine improves the outcome in childhood acute myeloid leukemia: the AML99 trial from the Japanese Childhood AML Cooperative Study Group. , 2009, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.